Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk | terminated | Phase 2 | 65 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03367676 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)(SOBER) | terminated | Phase 2 | 78 | Ruijin HospitalOTHER | 1 | Sep 23, 2026 |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07173101 | Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients(HEADBAND) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy(AIPAC-003) | terminated | Phase 2 / Phase 3 | 72 | Immutep S.A.S.INDUSTRY | 5 | Jul 30, 2026 | clinicaltrials |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | terminated | Phase 2 | 7 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer(ELONA) | terminated | Phase 1 / Phase 2 | 4 | Context Therapeutics Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | terminated | Phase 1 / Phase 2 | 15 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure | terminated | Phase 2 | 224 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT03632941 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | terminated | Phase 2 | 8 | Herbert LyerlyOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT03765983 | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | terminated | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05085002 | A Study of Lerociclib in Participants With Advanced Breast Cancer | terminated | Phase 2 | 100 | EQRx, Inc.INDUSTRY | 6 | May 14, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01472445 | Vitamin D and Breast Cancer: Does Weight Make a Difference? | terminated | Phase 2 | 41 | Melinda TelliOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01589861 | Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer(PIKHER2) | terminated | Phase 1 / Phase 2 | 24 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01980277 | Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer(TAKTIC) | terminated | Phase 1 / Phase 2 | 68 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05744375 | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab(TRANSCENDER) | terminated | Phase 2 | 2 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04791384 | Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Criterium, Inc.INDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | terminated | Phase 2 | 13 | Allarity TherapeuticsINDUSTRY | 7 | Mar 12, 2026 | clinicaltrials |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | terminated | Phase 1 / Phase 2 | 2 | Penn State UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | terminated | Phase 2 | 24 | Gordon Mills, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03130439 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | terminated | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05269160 | Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | terminated | Phase 1 / Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer(INTEGRAL) | terminated | Phase 2 | 8 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | terminated | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy(neoMono) | terminated | Phase 2 | 442 | Palleos Healthcare GmbHINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy(ELPIS) | terminated | Phase 2 | 5 | Fundacio Clinic BarcelonaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06851442 | Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer(TrasTUCAN) | terminated | Phase 2 | 13 | Spanish Breast Cancer Research GroupOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05180006 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy(BIS-Program) | terminated | Phase 2 | 33 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials